Cancer Immunotherapy Program News

Every person on your child’s team has the same goal: to give your child the best possible care. We provide medical care, emotional support and much more. Each team member has extensive experience in the treatment of children using immunotherapy.

How we serve you

Existing patients or family members

215-590-3025

New patients, referrals and second opinions

267-426-0762

Paulina walking outside with her parents

European Commission Approves Innovative CAR T-cell Therapy Pioneered at Children’s Hospital of Philadelphia

Aug 24, 2018

The European Commission (EC) approves Kymriah, the first-ever U.S. FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers.

Dr. Stephan Grupp to Lead Cellular Therapy and Transplant Section in CHOP Cancer Program

May 15, 2017

A leading pediatric oncologist at CHOP, Dr. Grupp is now Chief of the Section of Cellular Therapy and Transplant in the Hospital’s Division of Oncology.

CHOP’s Breakthrough Cancer Immunotherapy Program Receives Generous Grant from the Emily Whitehead Foundation

Apr 17, 2018

Emily Whitehead, the first pediatric patient to receive CAR T-cell therapy, and her family honor the CHOP team who saved her life with a $250,000 research grant to expand the use of the therapy for relapsed or refractory ALL.

T-cell Therapy Pioneered at CHOP Shows Persistent Benefits in Young Leukemia Patients

Feb 1, 2018

Updated results from a global clinical trial of the CAR T-cell therapy for ALL reveal that children and young adults continued to show high rates of durable, complete remission of their disease.

Recent FDA Approval Opens New Possibilities for CAR T-cell Therapies

Jul 31, 2018

CHOP has been at the forefront of developing cell therapy to treat ALL. Some next steps include initiating clinical trials for AML and, ultimately, making this treatment work for solid tumors.

Revolutionizing Cancer Treatment

Nov 8, 2017

Philanthropy helped CHOP develop the first cell therapy to receive FDA approval and provide lifesaving treatments to 170 children with ALL, like Paulina.

Pediatric Immunotherapy: What’s Next for CAR-T Therapy

Oct 20, 2017

The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.

FDA Approves Personalized Cellular Therapy for Advanced Leukemia Developed by University of Pennsylvania and Children’s Hospital of Philadelphia

Aug 30, 2017

This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.

Five Years Later, First Pediatric Recipient of CAR T-Cell Therapy Remains Cancer-free

Jul 12, 2017

Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.

FDA Committee Recommends Approving First Cell Therapy to Successfully Treat Cancer